Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Obseva Sa (OBSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA - May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates

ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OBSV : 12.71 (-2.61%)
ObsEva Reports First Quarter 2019 Financial Results

OBSV : 12.71 (-2.61%)
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

Geneva, Switzerland and Boston, MA - May 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA Announces that ObsEva's Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

Geneva, Switzerland and Boston, MA - May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
Consolidated Research: 2019 Summary Expectations for Corporacion America Airports S.A., Nasdaq, Constellation Brands, and ObsEva SA -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Corporacion America Airports S.A....

CAAP : 7.81 (-0.51%)
NDAQ : 90.26 (-0.04%)
OBSV : 12.71 (-2.61%)
STZ : 203.05 (-0.85%)
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

OBSV : 12.71 (-2.61%)
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

Geneva, Switzerland and Boston, MA -May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

Geneva, Switzerland and Boston, MA - April 29 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

Geneva, Switzerland and Boston, MA - March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

Geneva, Switzerland and Boston - March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

Geneva, Switzerland and Boston, MA -February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel...

OBSV : 12.71 (-2.61%)
ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA - February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Geneva, Switzerland and Boston, MA - January 23, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 12.71 (-2.61%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
AAON +0.83
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar